PEGS Boston - Protein Engineering Summit

April 8–12, 2019
Boston, MA, USA

Meet Genedata experts at PEGS in Boston, MA, USA.

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.

To get more information about Genedata solutions, please contact

Recommended Oral Presentations

Merck’s BRAIN – “Biologics Research All-In-One”: Building a Request System for Quality Control of Purified Proteins
Erin Williams, Associate Lab Head of Quality Control, EMD Serono

Engineering Antibodies - Emerging Technologies in Antibody Engineering
Thursday, April 11 | 9:35–10:05

We have established a global data and workflow platform at Merck for increasing the efficiency of our antibody discovery, protein production, and quality control processes.  We share examples of how the use of this platform has transformed our daily research work, e.g., in organizing and performing QC of produced proteins, including standard and bispecific antibodies, and how it supports discovery and engineering groups using B-cell cloning workflows and engineering of (SEED) bispecific antibodies.

Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CARs
Andrew Lynch, PhD, Scientific Consultant, Biologics, Genedata

Improving Immunotherapy Efficacy and Safety - Advances in Checkpoint Iinhibitors and IO Combinations
Monday, April 8 | 12:20–12:50

Novel classes of bio-molecules are currently evaluated for their use in cancer immunotherapy. Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs promise significant advantages. However, these highly engineered molecules pose new challenges in design, engineering, cloning, expression, purification, and analytics. We present an infrastructure that addresses these challenges and enables the industrialization of these various novel therapeutic platforms.

A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules
Christopher Smith, PhD, Head of Biologics US, Biologics, Genedata

Characterization of Biotherapeutics - Characterization Challenges of Bispecifics
Tuesday, April 9 | 3:05–3:35

We present a workflow system that enables systematic developability and manufacturability assessments, using both in silico and high throughput analytical confirmatory methods, over the entire biologics R&D process from initial discovery all the way to final candidate selection. We show use cases for mAbs and other complex multi/bispecific formats and discuss building predictive developability models utilizing this system. We also present the underlying molecule and task management needed for analytical organizations to accomplish this.